Approval · Notice of Compliance 24099 · 2020
JULUCA: Notice of Compliance 24099
Issued August 24, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24099
- Date
- August 24, 2020
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To change the labelling from an outer carton to an extended content label (ecl) with affixed patient insert/leaflet (efw)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JULUCA | Not yet assigned | — |
Medicinal ingredients
- RILPIVIRINE HYDROCHLORIDE 25 MG per TAB
- DOLUTEGRAVIR SODIUM 50 MG per TAB